

RECEIVED
CENTRAL FAX CENTER

001/005

DEC 06 2006

571-273-8300 CENTRAL FAX

PTO/SB/97 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on December 6, 2006
Date
SignatureNancy L. Doble

Typed or printed name of person signing Certificate

In re Application of: Andrea Savarino

Docket No.: 97728.00147

Serial No.: 10/783,268

Confirmation No.: 7328

Filing Date: February 20, 2004

Art Unit: 1617

Title: Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

ATTACHED HERETO:

1. Corrected Supplemental Information Disclosure Statement dated 12/6/06 (2 pages) and
2. Corrected PTO Information Disclosure Statement form PTO/SB/O8B (2 pages)

Total Number of Pages Transmitted including coversheet: 5

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

#5985757

REMITTED

DEC 06 2006

Serial No. 10/783,268

Attorney Docket No. 97728.00147

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is facsimile transmitted to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Facsimile No. 571-273-8300.

Date: December 6, 2006

Name: Nancy L. Doble

Signature: *Nancy L. Doble***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of Andrea Savarino)	Confirmation No.:	7328
)		
Serial No.: 10/783,268)	Art Unit:	1617
)		
Filing Date: February 20, 2004)		
)	Customer No.:	21832
For: Methods for Treatment of HIV or Malaria)		
Using Combinations of Chloroquine and)	Docket No.:	97728.00147
Protease Inhibitors)		

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

**CORRECTED SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This corrected supplemental information disclosure is submitted to correct a typographical error on form PTO/SB/08B which was previously filed with the United States Patent and Trademark Office on March 10, 2006. Copy of the corrected form PTO/SB/08B is attached. The foreign patent document cited as WO/92/0145 should be WO92/01451. This Corrected Supplemental Information Disclosure Statement is believed to be filed prior to the mailing date of a First Office Action regarding the above-referenced application.

Accordingly, no fee is believed to be required. However, if any fee is required, or otherwise if necessary to cover any deficiency in fees already paid, authorization is hereby given to charge our Deposit Account No. 50-3569.

Serial No. 10/792,415

Docket No. 97309.00098

Respectfully submitted,

Date: December 6, 2006

By: E. E. Grondahl
Eric E. Grondahl
Attorney for Applicants
Registration No. 46,741

PTO Correspondence Address:

McCarter & English, LLP
CityPlace I
185 Asylum Street
Hartford, CT 06103
Phone: (860) 275-6704
Fax: (860) 724-3397

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/783,268
				Filing Date	February 20, 2004
				First Named Inventor	Andrea Savarino
				An Unit	1617
				Examiner Name	Wang, Shengjun
Sheet	2	of	2	Attorney Docket Number	97728.00147

RECEIVED
CENTRAL FAX CENTER

DEC 06 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T ²
	1.	Treatment for HIV related inflammation, Treatment Review, May 1995 (no. 18) Abstract	
	2.	Hydroxychloroquine+ddl+hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, December 3, 1990 (No. 332)	
	3.	BOELAET, et al. The Additive I Vitro and Anti-HIV-1 Effect of Chloroquine When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology, 2001, Vol. 61, pages 1531-1535.	
	4.	CHUKWUEMEKA, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in ConComitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, Vol. 21, No. 9, 1999, pages 1456-1496	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ME16013122.1